In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NanoString Technologies completes its $50.2mm IPO

Executive Summary

Life sciences company NanoString Technologies Inc. (translational research and molecular diagnostics) has netted $50.2mm in an IPO of 5.4mm shares priced at $10; well below its anticipated $13-15 range.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register